	US 11,666,601 B2
	Synapse formation agent
Osamu Honmou, Hokkaido (JP); Masanori Sasaki, Hokkaido (JP); Rie Maezawa, Hokkaido (JP); Shinichi Oka, Hokkaido (JP); Yuko Sasaki, Hokkaido (JP); Masahito Nakazaki, Hokkaido (JP); and Toshihiko Yamashita, Hokkaido (JP)
Assigned to Sapporo Medical University, Hokkaido (JP); and Nipro Corporation, Osaka (JP)
Appl. No. 16/96,962
Filed by Sapporo Medical University, Sapporo (JP); and Nipro Corporation, Osaka (JP)
PCT Filed Apr. 26, 2017, PCT No. PCT/JP2017/017325 § 371(c)(1), (2) Date Oct. 26, 2018, PCT Pub. No. WO2017/188457, PCT Pub. Date Nov. 2, 2017.
Claims priority of application No. JP2016-091286 (JP), filed on Apr. 28, 2016; and application No. JP2016-091300 (JP), filed on Apr. 28, 2016.
Prior Publication US 2019/0117700 A1, Apr. 25, 2019
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61P 25/00 (2006.01); C12N 5/0775 (2010.01)

CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61P 25/00 (2018.01); C12N 5/0663 (2013.01)]

11 Claims

1. A method for promoting brain plasticity to treat a patient suffering from a chronic phase of cerebral infarction, comprising administering to the patient CD24-negative mesenchymal stem cells derived from human bone marrow or blood wherein the chronic phase of cerebral infarction occurs at least 150 days following an acute cerebral infarction, wherein promoting brain plasticity comprises promoting reconstruction of neuronal circuits and compensation by normal brain tissue in the patient, thereby treating the chronic phase of cerebral infarction.